At week 72, mean percentage weight loss was 15.0% with tirzepatide 5mg, 19.5% with 10mg, and 20.9% with 15mg, compared to just 3.1% with placebo
This low starting dose allows the body to adapt gradually before the dose is increased in a stepwise fashion over several months
Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials
Eating small, frequent meals and staying hydrated can reduce nausea duration by 3040% compared to patients who don't adjust their diet
Buying research-grade Retatrutide in Canada Retatrutide, development code LY3437943, is a synthetic peptide designed as a triple agonist targeting GLP-1, GIP, and the glucagon receptor
The decision depends on: Your menopause symptoms (hot flashes, mood, sleep, etc.) Cardiovascular risk factors Personal and family medical history Your goals beyond just weight loss What to ask your doctor: Would HRT address symptoms Im experiencing beyond weight
